Respiratory eHealth company Adherium (ASX:ADR) has announced the appointment of Tara Creaven-Capasso as its vice president of quality, regulatory and clinical affairs.
The company also announced that Robert Spurr’s assignment as the chief financial officer has concluded and recruiting for the backfill of this Melbourne-based position is progressing.
CEO Rick Legleiter said, “At this pivotal time in our growth strategy, we are extremely pleased to welcome Tara further strengthening our team. Her commercial pathway experience with the regulatory strategy and clinical trial management along with her excellent relationships and extensive background in successfully negotiating with the FDA and other regulatory bodies will drive Adherium’s market expansion forward.”
Ms Creaven-Capasso said, “I have dedicated my career to bringing innovative technologies to market, for the purpose of improving patient’s quality of life, while solving clinical problems.
"Development of robust regulatory strategies and quality management systems is essential when looking to commercialise and achieve market access of high quality, competitive, and compliant products. I am honoured to take on a broader role with the Adherium team to help deliver on its mission. I look forward to applying my expertise in guiding the company as it continues to build on its commercial strategies.”